148 related articles for article (PubMed ID: 37142929)
21. A high-throughput, multiplex cell death assay using an RNAi screening approach.
Falkenberg KJ; Saunders DN; Simpson KJ
Cold Spring Harb Protoc; 2014 Jun; 2014(6):663-76. PubMed ID: 24890208
[TBL] [Abstract][Full Text] [Related]
22. Designing zebrafish chemical screens.
Peterson RT; Fishman MC
Methods Cell Biol; 2011; 105():525-41. PubMed ID: 21951546
[TBL] [Abstract][Full Text] [Related]
23. High-Throughput Spheroid Screens Using Volume, Resazurin Reduction, and Acid Phosphatase Activity.
Ivanov DP; Grabowska AM; Garnett MC
Methods Mol Biol; 2017; 1601():43-59. PubMed ID: 28470516
[TBL] [Abstract][Full Text] [Related]
24. High Content, Phenotypic Assays and Screens for Compounds Modulating Cellular Processes in Primary Neurons.
Kepiro M; Varkuti BH; Davis RL
Methods Enzymol; 2018; 610():219-250. PubMed ID: 30390800
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.
Ngo A; Koay A; Pecquet C; Diaconu CC; Jenkins DA; Shiau AK; Constantinescu SN; Choong ML
Methods Mol Biol; 2018; 1787():53-66. PubMed ID: 29736709
[TBL] [Abstract][Full Text] [Related]
26. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.
Nishi M; Akutsu H; Kudoh A; Kimura H; Yamamoto N; Umezawa A; Lee SW; Ryo A
Oncotarget; 2014 Sep; 5(18):8665-80. PubMed ID: 25228591
[TBL] [Abstract][Full Text] [Related]
27. Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?
Eglen RM; Randle DH
Assay Drug Dev Technol; 2015 Jun; 13(5):262-5. PubMed ID: 26121065
[TBL] [Abstract][Full Text] [Related]
28. Method Development and Application of an Accelerated Solution Stability Screen for Drug Discovery.
Gomez-Sanchez R; Besley S; Zeliku Z; Young RJ
SLAS Discov; 2020 Dec; 25(10):1191-1196. PubMed ID: 32522054
[TBL] [Abstract][Full Text] [Related]
29. A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery.
Joslin J; Gilligan J; Anderson P; Garcia C; Sharif O; Hampton J; Cohen S; King M; Zhou B; Jiang S; Trussell C; Dunn R; Fathman JW; Snead JL; Boitano AE; Nguyen T; Conner M; Cooke M; Harris J; Ainscow E; Zhou Y; Shaw C; Sipes D; Mainquist J; Lesley S
SLAS Discov; 2018 Aug; 23(7):697-707. PubMed ID: 29843542
[TBL] [Abstract][Full Text] [Related]
30. A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes.
De Rycker M; O'Neill S; Joshi D; Campbell L; Gray DW; Fairlamb AH
PLoS Negl Trop Dis; 2012; 6(11):e1932. PubMed ID: 23209868
[TBL] [Abstract][Full Text] [Related]
31. High-content screening of natural products reveals novel nuclear export inhibitors.
Cautain B; de Pedro N; Murillo Garzón V; Muñoz de Escalona M; González Menéndez V; Tormo JR; Martin J; El Aouad N; Reyes F; Asensio F; Genilloud O; Vicente F; Link W
J Biomol Screen; 2014 Jan; 19(1):57-65. PubMed ID: 24045581
[TBL] [Abstract][Full Text] [Related]
32. In vitro assays and techniques utilized in anticancer drug discovery.
Ediriweera MK; Tennekoon KH; Samarakoon SR
J Appl Toxicol; 2019 Jan; 39(1):38-71. PubMed ID: 30073673
[TBL] [Abstract][Full Text] [Related]
33. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening.
Grzelak EM; Choules MP; Gao W; Cai G; Wan B; Wang Y; McAlpine JB; Cheng J; Jin Y; Lee H; Suh JW; Pauli GF; Franzblau SG; Jaki BU; Cho S
J Antibiot (Tokyo); 2019 Oct; 72(10):719-728. PubMed ID: 31292530
[TBL] [Abstract][Full Text] [Related]
34. Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.
Vasou A; Paulus C; Narloch J; Gage ZO; Rameix-Welti MA; Eléouët JF; Nevels M; Randall RE; Adamson CS
Antiviral Res; 2018 Feb; 150():79-92. PubMed ID: 29037975
[TBL] [Abstract][Full Text] [Related]
35. The evolution of library design: crafting smart compound collections for phenotypic screens.
Spear KL; Brown SP
Drug Discov Today Technol; 2017 Mar; 23():61-67. PubMed ID: 28647087
[TBL] [Abstract][Full Text] [Related]
36. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
37. A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation.
McShane MP; Friedrichson T; Giner A; Meyenhofer F; Barsacchi R; Bickle M; Zerial M
J Biomol Screen; 2015 Jul; 20(6):720-8. PubMed ID: 25838434
[TBL] [Abstract][Full Text] [Related]
38. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
Mukherjee R; Chandra Pal A; Banerjee M
Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
[TBL] [Abstract][Full Text] [Related]
39. High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress.
Thorne N; Malik N; Shah S; Zhao J; Class B; Aguisanda F; Southall N; Xia M; McKew JC; Rao M; Zheng W
Stem Cells Transl Med; 2016 May; 5(5):613-27. PubMed ID: 27034412
[TBL] [Abstract][Full Text] [Related]
40. High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers.
Martin HL; Adams M; Higgins J; Bond J; Morrison EE; Bell SM; Warriner S; Nelson A; Tomlinson DC
PLoS One; 2014; 9(2):e88338. PubMed ID: 24505478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
